Longeveron (LGVN) Projected to Post Quarterly Earnings on Friday

Longeveron (NASDAQ:LGVN) is anticipated to post its Q4 2025 results before the market opens on Friday, February 27th. Analysts expect Longeveron to post earnings of ($0.42) per share and revenue of $0.11 million for the quarter. Parties are encouraged to explore the company’s upcoming Q4 2025 earning overview page for the latest details on the call scheduled for Friday, February 27, 2026 at 4:00 PM ET.

Longeveron Trading Down 0.3%

Shares of LGVN stock opened at $0.56 on Friday. The company has a 50 day simple moving average of $0.56 and a two-hundred day simple moving average of $0.71. The stock has a market cap of $11.94 million, a P/E ratio of -0.53 and a beta of 0.21. Longeveron has a 12 month low of $0.49 and a 12 month high of $1.92.

Analyst Ratings Changes

Separately, Weiss Ratings reiterated a “sell (e+)” rating on shares of Longeveron in a research report on Thursday, January 22nd. Two research analysts have rated the stock with a Buy rating and one has issued a Sell rating to the company. According to data from MarketBeat.com, the company presently has an average rating of “Hold” and an average price target of $6.50.

Institutional Trading of Longeveron

An institutional investor recently bought a new position in Longeveron stock. XTX Topco Ltd purchased a new stake in Longeveron Inc. (NASDAQ:LGVN) in the second quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The fund purchased 48,003 shares of the company’s stock, valued at approximately $62,000. XTX Topco Ltd owned 0.32% of Longeveron as of its most recent filing with the Securities and Exchange Commission (SEC). 10.01% of the stock is owned by institutional investors.

About Longeveron

Longeveron Inc is a clinical-stage biotechnology company focused on the development and commercialization of allogeneic cellular therapies designed to address aging-related and inflammatory conditions. The company’s primary therapeutic candidate, Lomecel-B, is an off-the-shelf mesenchymal stem cell product derived from bone marrow. Through its proprietary manufacturing process, Longeveron aims to produce a consistent, scalable cell therapy platform with potential applications in multiple disease areas.

Longeveron’s pipeline encompasses several ongoing and completed clinical studies.